LYVE1 and breast cancer: In addition, nude mice that were intradermally injected with MDA‐MB‐231 breast cancer cells and treated with the LYVE‐1 monoclonal antibody demonstrated reduced primary tumor growth with the caveat that this model lacks T cells and thus does not recapitulate the tumor immune microenvironment.